Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Research & Development (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Research & Development for 17 consecutive years, with $25.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 20.81% to $25.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $106.8 million, a 5.82% decrease, with the full-year FY2025 number at $106.8 million, down 5.82% from a year prior.
  • Research & Development was $25.5 million for Q4 2025 at Myriad Genetics, down from $28.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $32.2 million in Q4 2024 to a low of $18.8 million in Q3 2021.
  • A 5-year average of $23.8 million and a median of $23.2 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 42.74% in 2021, then soared 53.33% in 2024.
  • Myriad Genetics' Research & Development stood at $20.5 million in 2021, then grew by 14.15% to $23.4 million in 2022, then fell by 10.26% to $21.0 million in 2023, then surged by 53.33% to $32.2 million in 2024, then dropped by 20.81% to $25.5 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Research & Development are $25.5 million (Q4 2025), $28.2 million (Q3 2025), and $25.6 million (Q2 2025).